A major new finding of this study is that, depending on the drug-IR schedule, the MEK inhibitor PD184352 promoted either the radiosensitizing activity of NVP-AUY922 in the glioblastoma SNB19 cell line or a cytostatic effect in both tested cell lines. The gene discussed is MAP2K7; the disease is glioblastoma.